Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Switch from IV Epoprostenol to IV Remodulin in PAH
NCT00643604Phase 4Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Mar 2008
- Primary completion
- Jan 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension due to lung disease (PH), sponsored by United Therapeutics Corporation. Primary endpoint: Change in Six Minute Walk Distance at Week 8. Started Mar 2008; status: terminated.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)pulmonary hypertension due to lung disease (PH)
Beyond the preview
Go deeper on NCT00643604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00643604.